Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\29079639
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Clin+Sci+(Lond)
2017 ; 131
(21
): 2627-2642
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Immune checkpoint inhibitors in renal cell carcinoma
#MMPMID29079639
Ross K
; Jones RJ
Clin Sci (Lond)
2017[Nov]; 131
(21
): 2627-2642
PMID29079639
show ga
The immune system has long been known to play a critical role in the body's
defence against cancer, and there have been multiple attempts to harness it for
therapeutic gain. Renal cancer was, historically, one of a small number of tumour
types where immune manipulation had been shown to be effective. The current
generation of immune checkpoint inhibitors are rapidly entering into routine
clinical practice in the management of a number of tumour types, including renal
cancer, where one drug, nivolumab, an anti-programmed death-1 (PD-1) monoclonal
antibody (mAb), is licensed for patients who have progressed on prior systemic
treatment. Ongoing trials aim to maximize the benefits that can be gained from
this new class of drug by exploring optimal timing in the natural course of the
disease as well as combinations with other checkpoint inhibitors and drugs from
different classes.
|Angiogenesis Inhibitors/therapeutic use
[MESH]
|Animals
[MESH]
|Antibodies, Monoclonal/adverse effects/*therapeutic use
[MESH]
|Antineoplastic Agents/adverse effects/*therapeutic use
[MESH]
|Antineoplastic Combined Chemotherapy Protocols/therapeutic use
[MESH]
free
free
free
